Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

Sep 18, 2020

Roche Announces Results of EMPACTA Study for Chugai’s Actemra for the Treatment of COVID-19

TOKYO, September 18, 2020 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release today regarding results of EMPACTA study for Actemra®/RoActemra® [generic name: tocilizumab (genetical recombination)] for the treatment of COVID-19. Actemra is a humanized anti-human IL-6 receptor monoclonal antibody created by Chugai.

Please refer to the link below for details of the press release:

Trademarks used or mentioned in this release are protected by laws.

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Toshiya Sasai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp
  • Like
  • Tweet
  • LINE it!
  • E-mail
Back to top